Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.77 |
| ▸ | FPR1 | P21462 | 2/20 | 0.44 |
| ▸ | FPR2 | P25090 | 2/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6270626 | 0.90 | F10 (0.79) | F10FPR1FPR2ALDH1A1F2 | |
| SCHEMBL6323784 | 0.90 | F10 (0.79) | F10FPR1FPR2ALDH1A1F2 | |
| SCHEMBL6839419 | 0.89 | F10 (0.78) | F10FPR1FPR2ALDH1A1F2 | |
| SCHEMBL6275874 | 0.89 | F10 (0.72) | F10FPR1FPR2ALDH1A1F2 | |
| SCHEMBL6240978 | 0.88 | F10 (0.77) | F10FPR1FPR2ALDH1A1F2 | |
| SCHEMBL6239895 | 0.88 | F10 (0.77) | F10FPR1FPR2ALDH1A1F2 | |
| SCHEMBL6241390 | 0.87 | F10 (0.75) | F10FPR1FPR2ALDH1A1F2 | |
| SCHEMBL6240505 | 0.87 | F10 (0.75) | F10FPR1FPR2F2PRSS1 | |
| SCHEMBL6241699 | 0.87 | F10 (0.75) | F10FPR1FPR2ALDH1A1F2 | |
| SCHEMBL6236705 | 0.87 | F10 (0.75) | F10FPR1FPR2ALDH1A1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167131-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. | 2004-08-26 | — | — | US | claimed |
| EP-1539686-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040167131-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004024679-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167131-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | TFPI, SERPINC1, F11 | F10 13/4885FPR1 582/4885FPR2 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.